Amphastar Pharma (AMPH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amphastar Pharmaceuticals (AMPH) PT Lowered to $22 at Needham & Company
August 9, 2018 1:38 PM EDTNeedham & Company lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $22.00 (from $24.00) while maintaining a Buy rating.
Analyst Serge Belanger remains positive as the recent approval of generic Isuprel, along with medroxyprogesterone and neostigmine will continue driving growth in... More
Amphastar Pharmaceuticals (AMPH) PT Lowered to $24 at Piper Jaffray
August 9, 2018 4:37 AM EDTPiper Jaffray lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $24.00 (from $26.00) while maintaining a Overweight rating.
... More